"Optimed Research, established over 25 years ago by Donald McNeil, MD, has grown from a stand alone research site into a network of sites across the country that specialize in Allergy, Immunology, Ophthalmology, Family Practice and Neurology/CNS. Optimed Site Services, a subsidiary of Optimed Research, was formed in early 2019. We identified early on that research sites are more powerful when they work together. Our research experience partnered with a specialist clinical experience makes for a powerful partnership. This strategic partnership allows us to focus on the administrative, regulatory and trial oversight so the investigator can focus on the clinical oversight."

During the past decade, Optimed Research, LTD conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 23 clinical trials were completed, i.e. on average, 76.7% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 12 clinical trials were completed. i.e. 70.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Optimed Research, LTD" #1 sponsor was "Shire" with 10 trials, followed by "Pfizer" with 9 trials sponsored, "Grifols Therapeutics LLC" with 5 trials sponsored, "Celgene" with 3 trials sponsored and "Kedrion S.p.A." with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Optimed Research, LTD" #1 collaborator was "Takeda Development Center Americas, Inc." with 3 trials as a collaborator, "Atlantic Research Group" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Dyax Corp." with 1 trials as a collaborator and "Institut de Recherches Internationales Servier" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Optimed Research, LTD" are "Hereditary Angioedema (HAE)" (6 trials), "Primary Immunodeficiency" (5 trials), "Hereditary Angioedema" (4 trials), "Osteoarthritis" (4 trials) and "Angioedema" (3 trials). Many other conditions were trialed in "Optimed Research, LTD" in a lesser frequency.

Most popular intervention types in "Optimed Research, LTD" are "Drug" (41 trials), "Biological" (13 trials), "Other" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "ecallantide" (3 trials), "CC-93538" (2 trials), "Kedrion IVIG 10%" (2 trials) and "Lanadelumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Optimed Research, LTD" are 52 trials for "All" genders.

Currently, there are NaN active trials in "Optimed Research, LTD". undefined are not yet recruiting, 8 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 36 completed trials in Optimed Research, LTD, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Optimed Research, LTD, 4 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".